Ipierian Hires New CEO to Carry on With Stem Cells for Discovering Neurological Drugs

Ipierian Hires New CEO to Carry on With Stem Cells for Discovering Neurological Drugs

xconomy | September 7, 2011 | By Luke Timmerman

iPierian, the South San Francisco-based developer of stem cell technology co-founded by top scientists at Harvard University, said today it has hired a new CEO. Nancy Stagliano, the co-founder and former CEO of South San Francisco-based CytomX Therapeutics, has taken the top job at iPierian, while interim CEO Peter Van Vlasselaer has moved aside to become the executive chairman of the board.

The company has been quiet since May, when Xconomy broke the news that the iPierian’s board terminated CEO Mike Venuti and most of the senior management team. A few weeks later, board chairman Corey Goodman resigned in the wake of the company’s shift in strategy. Today’s statement from iPierian says that Van Vlasselaer, the interim CEO, has prioritized the company’s efforts over the past several months toward using its stem cell technology to help discover drugs for neurodegenerative disorders like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy.

Click HERE or on the image below to read more…

About these ads

One Response to Ipierian Hires New CEO to Carry on With Stem Cells for Discovering Neurological Drugs

  1. Perth ergonomic office chair…

    [...]Ipierian Hires New CEO to Carry on With Stem Cells for Discovering Neurological Drugs « SMAHeadlines.com[...]…

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 31 other followers

%d bloggers like this: